Genomic Health’s research collaboration with Janssen Pharmaceuticals will evaluate the Oncotype DX Genomic Prostate Score test for potential drug development.
Genomic Health, Inc. today announced a multi-year research collaboration agreement with Janssen Pharmaceuticals to evaluate the Oncotype DX Genomic Prostate Score (GPS) test for their prostate cancer drug pipeline.
As part of the agreement, Genomic Health will test samples from Janssen studies to examine the association of GPS results with clinical outcomes.
Phil Febbo, M.D., chief medical officer at Genomic Health, said the move “may reveal potential for guiding treatment selection for prostate cancer patients in the future.”
The company also recently made a $4 million equity investment to further strengthen its partnership with Biocartis to develop an in vitro diagnostic (IVD) version of the Oncotype DX Breast Recurrence Score test on the Biocartis Idylla platform that can be performed locally by laboratory partners and in hospitals around the world.
Genomic Health, Inc. provides genomic-based diagnostic tests that help optimize cancer care, including addressing the overtreatment of the disease.
(Source: Genomic Health, Inc.)
Filed Under: Drug Discovery
